Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 17Squamous Cell Carcinoma of Head and Neck 5Skin Neoplasms 5Neoplasm Metastasis 5Melanoma 5Lung Neoplasms 5Carcinoma 5Recurrence 4Neoplasms 4Mouth Neoplasms 3Glioblastoma 3Colorectal Neoplasms 3Colonic Neoplasms 3Carcinoma, Renal Cell 3Breast Neoplasms 3Adenocarcinoma 3Ovarian Neoplasms 2Mycosis Fungoides 2Multiple Myeloma 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, B-Cell 2Laryngeal Neoplasms 2Fallopian Tube Neoplasms 2Carcinoma, Squamous Cell 2Vaccinia 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Carcinoma, Anaplastic 1Solid Tumors 1

Interventions

cemiplimab 1Transdermal Patch 1Doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cutaneous Squamous Cell Carcinoma × cemiplimab × 90 days × Clear all
NCT03969004 2026-03-27

Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma

Regeneron Pharmaceuticals

Phase 3 Active not recruiting
415 enrolled 1 FDA
Dermatologic

Cutaneous Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡